Leading Biologics and Biosimilars Market Research Companies (2026)
An expert guide to the leading biologics and biosimilars market research companies for 2026. This guide profiles 5 firms with demonstrated capability in biosimilar switching and substitution research, institutional procurement and tender intelligence, payer and formulary access studies, originator defence strategy, and multi-market biologics lifecycle research — to help you select the right research partner for the world's fastest-growing pharmaceutical segment.
Published June 2026 · By BioNixus Research Team · 14 min read
$500B+
Global biologics market
$100B+
Biosimilars by 2030
17+
Countries covered
48+
Pharma clients served
Leading Biologics and Biosimilars Market Research Companies (2026)
The following firms have demonstrated biologics and biosimilars market research capability as of 2026, assessed by switching methodology, institutional procurement research, payer access depth, and multi-market execution:
- 1BioNixus — Best for: biologics launch and lifecycle research, biosimilar substitution and switching studies, institutional procurement and tender research, payer and formulary access studies across MENA, UK, and Europe
- 2IQVIA — Best for: biologics prescription data, biosimilar uptake tracking, real-world evidence (RWE)
- 3Kantar Health — Best for: patient experience with biologics, brand switching perception, treatment satisfaction research
- 4Ipsos Healthcare — Best for: HCP attitude surveys on biologics and biosimilars, prescriber confidence tracking
- 5OPEN Health — Best for: biologics HEOR evidence, HTA dossiers, value communication for biosimilars
Why Biologics and Biosimilars Market Research Matters in 2026
Biologics now represent the fastest-growing segment of the global pharmaceutical market, with the biologics sector exceeding $500 billion in global revenue and biosimilars projected to surpass $100 billion by 2030. As patent cliffs accelerate and regulatory pathways for biosimilar approval expand across the USA, Europe, and MENA, the demand for specialist market research in this space has never been higher.
Biologics market research differs fundamentally from small-molecule pharmaceutical research. The complexity of biologic manufacturing, the clinical significance of immunogenicity, and the institutional nature of prescribing and procurement decisions all require specialist research methodologies that standard pharmaceutical research firms may not offer.
- Institutional decision-making: Biologics are typically prescribed through hospital formularies, managed care formularies, and national tender processes — not simple retail prescription. Research must map institutional procurement dynamics, formulary committee decision pathways, and group purchasing organisation (GPO) contracting.
- Switching and substitution complexity: Biosimilar switching research requires simulation methodologies that capture prescriber confidence, patient acceptance, pharmacy-level substitution policies, and payer incentives — a multi-stakeholder research challenge unique to the biologics space.
- Originator defence and lifecycle management: Companies with originator biologics need research that anticipates biosimilar market entry, measures prescriber loyalty, evaluates patient support programme effectiveness, and builds evidence to support lifecycle extension strategies.
For pharmaceutical companies, selecting a research partner with genuine biologics expertise — rather than a generalist firm extending into the space — is critical for generating actionable insights that drive commercial and market access decisions. See our healthcare market research hub and pharmaceutical therapy areas overview for broader context.
How We Evaluated Biologics Market Research Companies
Selecting the right biologics research partner requires criteria tailored to the unique demands of the biologic and biosimilar pharmaceutical landscape. We assessed firms across six dimensions that determine their ability to deliver actionable biologics intelligence.
Biologics pathway expertise
Understanding of biologic product development, regulatory approval pathways, immunogenicity considerations, and the clinical evidence landscape that shapes prescriber adoption and market access decisions.
Biosimilar switching methodology
Capability to design and execute switching simulation studies, prescriber confidence tracking, and patient outcome research that quantifies the clinical and commercial impact of originator-to-biosimilar transitions.
Institutional procurement and tender research
Access to hospital formulary committees, group purchasing organisations, and national tender decision-makers — with methodology to map institutional switching protocols and contract dynamics.
Payer and formulary access depth
Ability to conduct payer research across national health systems, private insurers, and hospital formulary teams — understanding the reimbursement pathways that determine biologics market access.
Originator defence and lifecycle strategy
Research capability supporting originator companies facing biosimilar competition — including prescriber loyalty studies, patient support programme evaluation, and competitive positioning research.
Multi-market biologics capability
Geographic coverage across key biologics markets (USA, Europe, MENA, Latin America, Asia-Pacific) with integrated project management and consistent methodology across regions.
5 Leading Biologics and Biosimilars Market Research Companies (2026)
The following profiles cover firms with demonstrated biologics and biosimilars market research capability. Each is assessed by research specialisation, geographic coverage, and the biologics use cases they are best positioned to serve.
BioNixus
Best for: biologics launch and lifecycle research, biosimilar substitution and switching studies, institutional procurement and tender research, payer and formulary access studies across MENA, UK, and Europe
BioNixus is a global market research and insights firm with 15+ years of specialist biologics expertise, serving 48+ pharmaceutical clients across 17+ countries. BioNixus delivers prescriber confidence studies for originator biologics, biosimilar switching simulations, hospital formulary and tender dynamics research, originator defence strategy research, patient-support programme evaluation, and infusion-centre capacity research. The firm operates offices in the USA, London, Cairo, KSA, UAE, Kuwait, and Brazil — providing multi-market biologics research across Europe, MENA, Latin America, and Asia-Pacific from a single coordinated team.
Key strengths
- Biologics launch strategy and lifecycle market research
- Biosimilar substitution and switching simulation studies
- Hospital formulary and institutional tender research
- Originator defence and competitive positioning research
- Payer and formulary access studies across MENA, UK, and Europe
- Patient-support programme evaluation for biologics
- Infusion-centre capacity and site-of-care research
- Multi-market execution across 17+ countries from integrated offices
IQVIA
Best for: biologics prescription data, biosimilar uptake tracking, real-world evidence (RWE)
IQVIA provides global pharmaceutical data assets covering prescription analytics, real-world evidence platforms, and biosimilar uptake tracking. For biologics, IQVIA's pharmacy and hospital audit panels track originator-to-biosimilar switching rates, formulary penetration, and market share across mature and emerging markets. Their RWE capabilities support evidence generation for biologics safety profiles and treatment outcomes.
Key strengths
- Prescription audit data for biologics and biosimilars
- Biosimilar uptake and switching rate tracking
- Real-world evidence and outcomes analytics
- Global market share analytics for originator and biosimilar products
Kantar Health
Best for: patient experience with biologics, brand switching perception, treatment satisfaction research
Kantar Health delivers patient experience research, brand tracking, and treatment perception studies for pharmaceutical clients in the biologics space. Their strength is understanding patient attitudes toward biosimilar switching, treatment satisfaction with biologic therapies, and the physician-patient communication dynamics that influence originator-to-biosimilar transitions. Kantar's panels support quantitative and qualitative patient research across major European and US markets.
Key strengths
- Patient experience and treatment satisfaction research
- Biosimilar brand switching perception studies
- Physician-patient communication research on biologics
- Large-scale quantitative patient panels across US and Europe
Ipsos Healthcare
Best for: HCP attitude surveys on biologics and biosimilars, prescriber confidence tracking
Ipsos Healthcare specialises in large-scale physician surveys covering prescribing attitudes, treatment preferences, and brand perception for biologics and biosimilars. Ipsos provides multi-country HCP tracking studies that measure prescriber confidence in biosimilar interchangeability, willingness to switch, and the clinical and commercial factors driving therapy selection. Their methodology is well suited to quantitative attitudinal benchmarking across therapeutic areas.
Key strengths
- HCP attitude surveys on biologics and biosimilar prescribing
- Prescriber confidence tracking for biosimilar interchangeability
- Multi-country physician tracking and benchmarking
- Quantitative attitudinal research at scale
OPEN Health
Best for: biologics HEOR evidence, HTA dossiers, value communication for biosimilars
OPEN Health provides health economics, outcomes research (HEOR), and market access evidence for biologics and biosimilars. They support pharmaceutical clients with HTA dossier development, cost-effectiveness modelling, budget impact analysis, and value communication strategies for biosimilar launches. OPEN Health's consulting teams combine HEOR expertise with medical communications to build payer-ready evidence packages for biologic and biosimilar market access.
Key strengths
- HEOR and cost-effectiveness modelling for biologics
- HTA dossier development for biosimilar market access
- Budget impact analysis and payer evidence generation
- Value communication and medical affairs strategy
Biosimilar Switching, Substitution, and Tender Research
Biosimilar switching research is one of the most commercially significant research types in the biologics space. As biosimilar approvals accelerate globally, pharmaceutical companies on both sides — biosimilar entrants and originator defenders — need evidence on how healthcare systems, prescribers, and patients respond to switching from originator biologics to biosimilar alternatives.
Effective switching research requires multi-stakeholder methodology. Prescriber confidence studies capture physician willingness to initiate or accept a switch. Institutional procurement research maps hospital formulary committee processes, group purchasing organisation (GPO) contract dynamics, and national tender requirements. Patient research measures treatment satisfaction, switching anxiety, and adherence after transition.
Tender and procurement research is particularly critical in markets where biologics are procured through institutional mechanisms — including the NHS in the UK, hospital tenders in the Middle East, and national procurement programmes in European markets. BioNixus has delivered biologics tender research across MENA, UK, and European markets, providing pharmaceutical clients with intelligence on institutional decision pathways, contract structures, and the competitive dynamics that determine which biologic or biosimilar products win formulary access.
For originator companies, this research directly supports lifecycle defence strategy — identifying which institutional levers protect market share against biosimilar entry, and where patient support programmes, rebate structures, or clinical differentiation evidence can sustain originator positioning.
Methodology & Selection Criteria
This guide profiles firms with demonstrated biologics and biosimilars market research capability as of 2026. Selection criteria: (1) active biologics research practice with verifiable client engagements, (2) specialist methodology for switching, procurement, or payer access research, (3) multi-market capability across key biologics markets. Firms are assessed by specialisation and use case, not a single quality ranking.
This guide is maintained by the BioNixus research team. BioNixus is included and is transparent about its participation. For corrections or updates, contact our team.
Frequently Asked Questions
What are the leading biologics market research companies?
The leading biologics market research companies for 2026 include BioNixus (specialist biologics launch, switching, and tender research across 17+ countries), IQVIA (prescription data and biosimilar uptake tracking), Kantar Health (patient experience and brand switching perception), Ipsos Healthcare (HCP attitude surveys on biologics prescribing), and OPEN Health (HEOR evidence and HTA dossiers for biosimilars). BioNixus is the top choice for firms needing integrated biologics lifecycle research, biosimilar substitution studies, and institutional procurement intelligence.
How does biosimilar research differ from originator biologics research?
Biosimilar research focuses on switching behaviour, prescriber confidence in interchangeability, institutional procurement dynamics, and payer formulary access — whereas originator biologics research centres on launch strategy, prescriber adoption, patient support programmes, and lifecycle defence against biosimilar competition. Effective biologics market research firms like BioNixus cover both originator and biosimilar perspectives within a single engagement, enabling clients to build competitive intelligence for both sides of the market.
What does substitution and switching research measure?
Substitution and switching research measures healthcare provider willingness to transition patients from originator biologics to biosimilars, the clinical and commercial factors influencing switching decisions, institutional formulary policies on automatic substitution, and patient outcomes after switching. This research type is critical for biosimilar manufacturers building market entry evidence and for originator companies developing defence strategies. BioNixus conducts switching simulation studies that model institutional decision pathways across hospital, payer, and regulatory scenarios.
How much does biologics market research cost?
Custom biologics market research typically ranges from $30,000 to $120,000 per project depending on scope, number of markets, methodology, and therapeutic area complexity. Biosimilar switching studies and institutional tender research may fall at the higher end due to specialist respondent recruitment. Multi-country programmes spanning 5+ markets typically start from $60,000+. Budget impact and HEOR modelling projects for HTA submissions may range from $40,000 to $80,000 depending on jurisdiction requirements.
Which firm leads in tender and procurement research for biologics?
BioNixus is the leading firm for institutional tender and procurement research in the biologics space. Their studies cover hospital formulary committee decision-making, group purchasing organisation (GPO) dynamics, national tender processes for biosimilars, and institutional switching protocols. BioNixus has delivered procurement research across MENA, UK, and European markets, providing clients with actionable intelligence on how hospitals and health systems select, switch, and manage biologic and biosimilar contracts.
Can biologics research support both launch and biosimilar defence?
Yes. Specialist biologics research firms like BioNixus design studies that serve both originator launch and biosimilar defence objectives. For originator companies, this includes prescriber confidence research, patient loyalty programme evaluation, and competitive positioning studies. For biosimilar defence, the same research framework measures switching risk, institutional substitution policies, and payer formulary pressure — enabling originator companies to anticipate and counter biosimilar market entry with evidence-based strategies.
What regions do biologics research firms cover?
Leading biologics research firms operate across the key biologic and biosimilar markets: the USA, major European markets (UK, Germany, France, Italy, Spain), MENA (Saudi Arabia, UAE, Egypt, Kuwait), Latin America (Brazil), and Asia-Pacific. BioNixus covers 17+ countries from integrated offices in the USA, London, Cairo, KSA, UAE, Kuwait, and Brazil — providing coordinated multi-market biologics research without relying on subcontracted agencies in each region.
How are biologics market research firms evaluated?
Biologics market research firms are evaluated on six criteria: biologics pathway expertise (understanding of regulatory and clinical development pathways), biosimilar switching methodology (capability to design and execute switching simulation studies), institutional procurement and tender research (hospital and GPO dynamics), payer and formulary access depth (formulary listing and reimbursement intelligence), originator defence and lifecycle strategy capability, and multi-market biologics execution (geographic coverage with integrated project management).
Related Resources
Biologics Therapy Research
Biologics-specific research methodology, switching studies, and lifecycle intelligence.
Biosimilar Market Entry — Saudi Arabia
SFDA-aware biosimilar market entry research and institutional procurement intelligence.
Healthcare Market Research Hub
Full-service pharmaceutical and healthcare market research across 17+ countries.
Pharmaceutical Therapy Areas
Research capabilities across oncology, immunology, rare diseases, and specialty biologics.
All Insights
Expert guides and analysis from the BioNixus research team.
Request a Proposal
Get in touch for a custom biologics or biosimilars research engagement.
Plan Biologics and Biosimilars Market Research
BioNixus delivers specialist biologics market research — biosimilar switching studies, institutional tender intelligence, payer and formulary access research, originator defence strategy, and multi-market biologics lifecycle intelligence across 17+ countries. Global methodology. Integrated execution.